loader from loading.io

Addressing Extracellular Matrix Breakdown That Leads to Age-Related Diseases with Dr. Sherif Idriss Elastin Biosciences TRANSCRIPT

Empowered Patient Podcast

Release Date: 09/24/2024

Driving Innovation in Cell Therapy Manufacturing  with Ryan Clarke Syntax Bio TRANSCRIPT show art Driving Innovation in Cell Therapy Manufacturing with Ryan Clarke Syntax Bio TRANSCRIPT

Empowered Patient Podcast

 Ryan Clarke, Co-Founder and CTO of Syntax Bio, is focused on solving manufacturing challenges in producing stem cell-derived therapies, specifically the process of stem cell differentiation. The Cellgorithm platform was designed to make differentiation an engineering problem by using a modified form of CRISPR to turn genes on and off in a specific, controlled sequence, reducing processing time from months to days and resulting in cost savings. One goal is to use AI and machine learning to build models capable of predicting optimal gene regulation sequences accelerating the discovery of...

info_outline
Driving Innovation in Cell Therapy Manufacturing  with Ryan Clarke Syntax Bio show art Driving Innovation in Cell Therapy Manufacturing with Ryan Clarke Syntax Bio

Empowered Patient Podcast

 Ryan Clarke, Co-Founder and CTO of Syntax Bio, is focused on solving manufacturing challenges in producing stem cell-derived therapies, specifically the process of stem cell differentiation. The Cellgorithm platform was designed to make differentiation an engineering problem by using a modified form of CRISPR to turn genes on and off in a specific, controlled sequence, reducing processing time from months to days and resulting in cost savings. One goal is to use AI and machine learning to build models capable of predicting optimal gene regulation sequences accelerating the discovery of...

info_outline
Origins and Future of Medical Imaging with Dr. David Sodickson Function Health TRANSCRIPT show art Origins and Future of Medical Imaging with Dr. David Sodickson Function Health TRANSCRIPT

Empowered Patient Podcast

Dr. Daniel Sodickson is Chief Medical Scientist at Function Health and author of the new book, The Future of Seeing: How Imaging Is Changing Our World. Building on the drive to improve medical imaging, AI and neural networks are now reshaping image interpretation and how and what data are collected. This approach produces high-quality results with minimal additional data and is inspiring innovative scanning techniques and equipment design. The future of medical imaging is the everywhere scanner, enhancing a single-shot session with a large hospital machine with continuous health...

info_outline
Origins and Future of Medical Imaging with Dr. David Sodickson Function Health show art Origins and Future of Medical Imaging with Dr. David Sodickson Function Health

Empowered Patient Podcast

Dr. Daniel Sodickson is Chief Medical Scientist at Function Health and author of the new book, The Future of Seeing: How Imaging Is Changing Our World. Building on the drive to improve medical imaging, AI and neural networks are now reshaping image interpretation and how and what data are collected. This approach produces high-quality results with minimal additional data and is inspiring innovative scanning techniques and equipment design. The future of medical imaging is the everywhere scanner, enhancing a single-shot session with a large hospital machine with continuous health...

info_outline
Stem Cell Therapy Aims to Rebuild Brain Circuits in Parkinson’s Patients with Dr. Howard Federoff Kenai Therapeutics TRANSCRIPT show art Stem Cell Therapy Aims to Rebuild Brain Circuits in Parkinson’s Patients with Dr. Howard Federoff Kenai Therapeutics TRANSCRIPT

Empowered Patient Podcast

Dr. Howard Federoff, Scientific Co-Founder, Chief Medical Officer, and Executive Vice President of Corporate Medicine and Science at Kenai Therapeutics, is developing a cell therapy for Parkinson's disease that involves transplanting IPSCs into the brain to replace lost dopamine neurons.  The goal is not to cure the underlying cause of the disease, but to restore motor function and reverse the disease's progression. Initial clinical focus was on patients with moderate to moderate-severe idiopathic Parkinson's, showing efficacy and safety, leading to expanding the study to include...

info_outline
Stem Cell Therapy Aims to Rebuild Brain Circuits in Parkinson’s Patients with Dr. Howard Federoff Kenai Therapeutics show art Stem Cell Therapy Aims to Rebuild Brain Circuits in Parkinson’s Patients with Dr. Howard Federoff Kenai Therapeutics

Empowered Patient Podcast

Dr. Howard Federoff, Scientific Co-Founder, Chief Medical Officer, and Executive Vice President of Corporate Medicine and Science at Kenai Therapeutics, is developing a cell therapy for Parkinson's disease that involves transplanting IPSCs into the brain to replace lost dopamine neurons.  The goal is not to cure the underlying cause of the disease, but to restore motor function and reverse the disease's progression. Initial clinical focus was on patients with moderate to moderate-severe idiopathic Parkinson's, showing efficacy and safety, leading to expanding the study to include...

info_outline
Transforming MRI Data to Identify Biomarkers for Diagnosing and Treating Back Pain with Brent Ness Aclarion TRANSCRIPT show art Transforming MRI Data to Identify Biomarkers for Diagnosing and Treating Back Pain with Brent Ness Aclarion TRANSCRIPT

Empowered Patient Podcast

Brent Ness, CEO and President of Aclarion,  highlights the challenges of diagnosing and treating chronic lower back pain, a leading driver of healthcare costs and opioid addiction. Traditional MRI and CT imaging do not reveal the biochemical source of pain within spinal discs, leading to misdiagnosis and unsuccessful treatment. The Aclarion technology uses MR spectroscopy to measure pain-causing biomarkers and, through a cloud-based, AI-powered SaaS model, analyzes the raw data and sends the physician a report within minutes. Brent explains, "The diagnosis and accurate treatment planning...

info_outline
Transforming MRI Data to Identify Biomarkers for Diagnosing and Treating Back Pain with Brent Ness Aclarion show art Transforming MRI Data to Identify Biomarkers for Diagnosing and Treating Back Pain with Brent Ness Aclarion

Empowered Patient Podcast

Brent Ness, CEO and President of Aclarion,  highlights the challenges of diagnosing and treating chronic lower back pain, a leading driver of healthcare costs and opioid addiction. Traditional MRI and CT imaging do not reveal the biochemical source of pain within spinal discs, leading to misdiagnosis and unsuccessful treatment. The Aclarion technology uses MR spectroscopy to measure pain-causing biomarkers and, through a cloud-based, AI-powered SaaS model, analyzes the raw data and sends the physician a report within minutes. Brent explains, "The diagnosis and accurate treatment planning...

info_outline
First Non-Steroidal MRA Drug Approved for Heart Failure with Dr. Alanna Morris-Simon Bayer TRANSCRIPT show art First Non-Steroidal MRA Drug Approved for Heart Failure with Dr. Alanna Morris-Simon Bayer TRANSCRIPT

Empowered Patient Podcast

Dr. Alanna Morris-Simon, Senior Medical Director for US Medical Affairs at Bayer, describes the symptoms and diagnostics used to classify heart failure and the key at-risk populations for this condition. The rapidly evolving landscape of heart failure treatments now includes the Bayer drug KERENDIA, a non-steroidal MRA approved to reduce cardiovascular death and heart failure in adults with an ejection fraction of 40% or more. This drug is part of an emerging trend to treat multiple related conditions simultaneously  and could prevent the onset of heart failure and treat established...

info_outline
First Non-Steroidal MRA Drug Approved for Heart Failure with Dr. Alanna Morris-Simon Bayer show art First Non-Steroidal MRA Drug Approved for Heart Failure with Dr. Alanna Morris-Simon Bayer

Empowered Patient Podcast

Dr. Alanna Morris-Simon, Senior Medical Director for US Medical Affairs at Bayer, describes the symptoms and diagnostics used to classify heart failure and the key at-risk populations for this condition. The rapidly evolving landscape of heart failure treatments now includes the Bayer drug KERENDIA, a non-steroidal MRA approved to reduce cardiovascular death and heart failure in adults with an ejection fraction of 40% or more. This drug is part of an emerging trend to treat multiple related conditions simultaneously  and could prevent the onset of heart failure and treat established...

info_outline
 
More Episodes

Dr. Sherif Idriss is the CEO of Elastin Biosciences, a company focused on targeting aging-related diseases by restoring elastin, a key protein in the extracellular matrix that provides elasticity and resilience to organs and tissues. They are developing small molecule therapies for diseases linked to elastin deficiency, including Williams syndrome and abdominal aortic aneurysm. As elastin degrades over time due to aging, it leads to loss of tissue structural integrity and function, contributing to numerous age-related diseases.  

Sherif explains, "One of the hallmarks of aging is the loss of the extracellular matrix, which is composed of several proteins. Collagen is quite famous, but also elastin is the other major protein that is responsible for the elasticity of the different organs. For example, in our skin, the loss of elastin is associated with us looking older and having all the aging signs and wrinkles on the skin. If you imagine that there are other organs inside that we don’t visually see, then you have also the blood vessels, the lungs, a lot of the connective tissue. The extracellular matrix proteins and elastin itself are also aging in the same way and have their own form of damage one way or another. All of this contributes to aging and aging-related diseases as well."

"Another kind of disease is the category of rare diseases. In this case, we aim to target Williams syndrome, a rare disease characterized by a genetic partial deletion of around 26 genes. One of these genes is elastin itself, so some genetic material is still there, but there is not enough. We would like to try to push the elastin production up in Williams syndrome, and this would help rectify a lot of the disease issues, particularly when it comes to the cardiovascular system because Williams syndrome patients have quite a lot of issues with the cardiovascular system from birth and all through life."

#ElastinBiosciences #Aging #AgingRelatedDiseases #Elastin #WilliamsSyndrome 

elastin-biosciences.com

Listen to the podcast here

Elastin